Pencil Biosciences is developing a fully synthetic gene modulation and editing platform that will have impact across a wide range of applications...
Laverock Therapeutics to commercialise the gene editing induced gene silencing (GEiGS®) platform for all human therapeutic applications.
Machine Discovery, a software company which uses machine learning technology to accelerate compute-intensive optimisation and simulation tasks, has secured £4.5-million of funding...
The UK Innovation and Science Seed Fund (UKI2S), independently managed by Future Planet Capital (Ventures), is unleashing support...
The new start-up will harness an AI-first approach to develop eco-friendly alternatives to everyday ingredients…
Investments in HALO X-ray Technologies will support regulatory approval of the first fieldable XRD system in checkpoint security...
Investment in the UK Innovation & Science Seed Fund (UKI2S), a driving force in supporting early-stage innovation and high-impact businesses, now totals £102m.
Bacterial resistance to antibiotics is growing as a critical worldwide challenge, often stated as the…
It’s been an exciting year for UKI2S, with £37 million additional capital into the fund,…
CEO of PreSymptom Health Extensive commercialisation experience, and a history of entrepreneurship, including the…